{"id":204437,"date":"2026-11-13T01:38:13","date_gmt":"2026-11-13T01:38:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/204437\/"},"modified":"2026-11-13T01:38:13","modified_gmt":"2026-11-13T01:38:13","slug":"blackstone-bets-1-5-billion-on-pfizer-obesity-drug-engineered-to-work-as-a-monthly-alternative-to-ozempic","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/204437\/","title":{"rendered":"Blackstone Bets $1.5 Billion on Pfizer Obesity Drug Engineered to Work as a Monthly Alternative to Ozempic"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"mapping-embed imgPhoto\" id=\"i478204\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/11\/employees-work-production-line-novo-nordisk-factory.jpg\" alt=\"Employees work production line Novo Nordisk factory\" width=\"836\" height=\"557\"\/><\/p>\n<p>Employees work on the production line at the Novo Nordisk factory in Hilleroed on September 26, 2023. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark, aiming to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. On June 12, 2023, the company announced plans to invest 15.9 billion Danish kroner to expand an existing Active Pharmaceutical Ingredient (API) production facility in the country. (Photo by Sergei GAPON \/ AFP)<br \/>\nSERGEI GAPON\/AFP via Getty Images<\/p>\n<p>Pfizer and Blackstone Life Sciences announced Wednesday that Blackstone-managed funds will cover up to $1.5 billion of development costs through 2028 for berobenatide, the pharmaceutical giant&#8217;s investigational once-monthly GLP-1 receptor agonist for obesity. Under the deal, Blackstone takes no equity stake and acquires no ownership rights in the drug; payments are milestone-based, tied to US regulatory approval of monthly berobenatide monotherapy for chronic weight management and to hitting certain commercial sales targets. Pfizer keeps full operational control.<\/p>\n<p>&#8220;Our aim is to bring important new medicines to patients while taking a disciplined approach that pairs internal research investments with targeted investment from capital partners,&#8221; said Cecile Guegan, Pfizer&#8217;s Chief Financial Officer. &#8220;Today&#8217;s announcement helps us advance our comprehensive obesity program and maintain the financial capacity and flexibility to invest in our broader pipeline across all therapeutic areas.&#8221;<\/p>\n<p>The deal is not just a financial story. What Blackstone is really betting on is a specific molecular engineering choice \u2014 one that, if it clears Phase 3, could change how hundreds of millions of people use GLP-1 drugs. Here is what makes berobenatide different from every weight-loss drug on the market today, and why the difference matters.<\/p>\n<p>Why Monthly Dosing Is Worth $1.5 Billion<\/p>\n<p>The word &#8220;monthly&#8221; does not sound revolutionary. But in the context of GLP-1 receptor agonist therapy \u2014 the class that includes Wegovy, Ozempic, and Zepbound \u2014 it represents a fundamental pharmacological challenge that no approved drug has yet solved.<\/p>\n<p>GLP-1 drugs work by mimicking glucagon-like peptide-1, a gut hormone that slows gastric emptying, signals satiety, and stimulates insulin release. The native hormone has a half-life of roughly two minutes, degraded almost instantly by an enzyme called dipeptidyl peptidase-4 (DPP-4). Drug developers have spent two decades engineering analogs that survive longer in circulation. Liraglutide (Victoza\/Saxenda) extended this to about 13 hours \u2014 enough for once-daily injections. Semaglutide (Ozempic\/Wegovy) pushed it to approximately 160 hours, achieving once-weekly dosing. Each step required molecular ingenuity to outsmart the body&#8217;s normal degradation machinery.<\/p>\n<p>Achieving monthly dosing \u2014 roughly 30 days of therapeutic effect per injection \u2014 requires another leap. And the engineering choices Metsera&#8217;s team made when designing berobenatide, before Pfizer <a rel=\"nofollow noopener\" href=\"https:\/\/www.businesswire.com\/news\/home\/20251112938725\/en\/Pfizer-Completes-Acquisition-of-Metsera\" class=\"external_red\" target=\"_blank\">completed the Metsera acquisition<\/a> for up to approximately $10 billion in November 2025, reflect a sophisticated layering of two distinct mechanisms.<\/p>\n<p>GLP-1 drug adherence is a documented clinical problem. Studies have consistently shown dropout rates above 50% within one to two years on weekly injectables, with injection frequency cited as a leading reason patients discontinue. Drugs that do not get taken do not reduce weight or protect hearts. Monthly dosing is not an incremental convenience upgrade; it is a potential structural solution to the adherence failure that limits weekly GLP-1s&#8217; real-world impact. That is what payers are watching, and what Blackstone is ultimately financing.<\/p>\n<p>The Two-Part Molecular Architecture<\/p>\n<p>Understanding why berobenatide might achieve monthly dosing requires understanding two distinct design features, each addressing a different biological problem.<\/p>\n<p>Part 1: Terminal Lipidation and Albumin Binding<\/p>\n<p>The first feature is terminal lipidation \u2014 the attachment of a fatty acid chain to the GLP-1 peptide. This is not new; semaglutide uses it. The strategy works because fatty acids bind reversibly and non-covalently to human serum albumin, the most abundant protein in blood plasma. Albumin has a half-life of approximately 19 days. When a GLP-1 peptide hitches a ride on albumin, it circulates much longer \u2014 slowing both renal clearance and enzymatic degradation.<\/p>\n<p>Semaglutide uses an 18-carbon fatty acid chain (C18) attached via a linker and spacer, achieving roughly 160-hour circulation. Berobenatide uses a longer fatty acid chain engineered for stronger albumin affinity. But there is a subtler and more important difference: most lipidated GLP-1 analogs must dissociate from albumin before binding their receptor. That dissociation step creates a bottleneck. Berobenatide&#8217;s lipid tail is engineered so the drug can bind the GLP-1 receptor with or without full dissociation from albumin \u2014 a pharmacokinetic property first documented in Metsera&#8217;s research and <a rel=\"nofollow noopener\" href=\"https:\/\/www.businesswire.com\/news\/home\/20260605120877\/en\/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide\" class=\"external_red\" target=\"_blank\">confirmed at ADA 2026<\/a>.<\/p>\n<p>The practical result: berobenatide maintains a reservoir of albumin-bound drug that can activate receptors continuously, extending effective half-life further than the lipid chain length alone would predict. This is why a 0.5 mL injection can be expected to remain pharmacologically active for approximately a month.<\/p>\n<p>Part 2: Biased Agonism \u2014 Rewiring Which Receptor Pathway Gets Activated<\/p>\n<p>The second feature is more conceptually novel and may ultimately be berobenatide&#8217;s more important scientific contribution: fully biased agonism.<\/p>\n<p>When any GLP-1 agonist binds the GLP-1 receptor, the receptor can activate two distinct intracellular signaling pathways. The first pathway \u2014 called the Gs\/cAMP pathway \u2014 drives the therapeutic effects: insulin secretion, satiety signaling, appetite suppression. The second pathway recruits a protein called beta-arrestin, which physically pulls the receptor off the cell surface and into an endosome, where it is recycled or degraded. Beta-arrestin recruitment is associated with receptor desensitization \u2014 reduced response to the drug over time \u2014 and is increasingly linked in preclinical research to the nausea and vomiting that cause so many patients to abandon GLP-1 therapy.<\/p>\n<p>A &#8220;biased&#8221; agonist is designed to selectively activate one pathway over the other. Berobenatide is described as &#8220;fully biased&#8221; \u2014 meaning it activates the cAMP pathway strongly while minimizing beta-arrestin recruitment. The result, as a <a rel=\"nofollow noopener\" href=\"https:\/\/penntoday.upenn.edu\/news\/understanding-glp-1-signaling-path-better-therapies\" class=\"external_red\" target=\"_blank\">February 2026 Penn study<\/a> published in Diabetes, Obesity and Metabolism demonstrated, is preservation of glycemic control with reduced GI side effects in preclinical models.<\/p>\n<p>&#8220;Berobenatide could be the first monthly GLP-1 receptor agonist,&#8221; said one obesity medicine specialist <a rel=\"nofollow noopener\" href=\"https:\/\/www.businesswire.com\/news\/home\/20260605120877\/en\/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide\" class=\"external_red\" target=\"_blank\">presenting at ADA 2026<\/a>. &#8220;The fully biased access to the receptor means that dual agonist-like weight loss should be possible.&#8221;<\/p>\n<p>The clinical significance of biased agonism in humans is not yet fully established; the Phase 3 program will produce the first large-scale evidence. But the mechanistic logic is sound: keeping receptors at the cell surface longer (by reducing internalization) simultaneously extends drug efficacy and may reduce the most common reason patients stop treatment.<\/p>\n<p>What Phase 2 Showed \u2014 and What It Did Not<\/p>\n<p>Berobenatide&#8217;s Phase 2 data, presented at ADA 2026, cleared the bar Pfizer needed to justify a 10-trial Phase 3 program. In the VESPER-1 open-label extension (Part B), participants escalated from placebo to 2.4 mg weekly berobenatide achieved a mean weight loss of 15.9% at week 60 \u2014 without plateau, suggesting continued weight loss beyond the trial&#8217;s initial observation period. VESPER-3, a 64-week placebo-controlled trial of monthly dosing, provided the data needed to advance the monthly dosing thesis specifically.<\/p>\n<p>The up to 12.3% placebo-adjusted weight loss on monthly berobenatide was lower than the 15.9% achieved with weekly dosing \u2014 a gap that Phase 3 investigators will need to characterize more precisely. But those numbers come with an important caveat: the VESPER trials were Phase 2b studies, designed for proof-of-concept, not for definitive comparison to competitors. Direct head-to-head comparisons with semaglutide or tirzepatide are not part of the VESPER Phase 3 program as currently announced.<\/p>\n<p>The safety profile was described by Dr. John B. Buse of the University of North Carolina School of Medicine, Chapel Hill as &#8220;consistent with the GLP-1 RA class, with no new safety signals&#8221; \u2014 a standard benchmark, though it means berobenatide still carries the class&#8217;s known profile: GI side effects (nausea, diarrhea, constipation), rare pancreatitis risk, and thyroid C-cell tumor observations in rodent studies that have not been reproduced in primates or humans.<\/p>\n<p>The Competition: Amgen and the Monthly Race<\/p>\n<p>Berobenatide is not racing alone toward once-monthly dosing. Amgen&#8217;s MariTide (maridebart cafraglutide) \u2014 a GLP-1 receptor agonist\/GIP receptor antagonist antibody-peptide conjugate \u2014 reported up to approximately 20% weight loss at 52 weeks in Phase 2 for patients with obesity without type 2 diabetes, and up to approximately 17% in obesity plus type 2 diabetes. MariTide&#8217;s <a rel=\"nofollow noopener\" href=\"https:\/\/www.amgen.com\/stories\/2025\/06\/inside-amgens-phase-3-maritime-program---advancing-the-future-of-obesity-care\" class=\"external_red\" target=\"_blank\">MARITIME Phase 3 program<\/a> is underway.<\/p>\n<p>The two drugs use different molecular architectures. MariTide is an antibody-peptide conjugate \u2014 a large-molecule biologic \u2014 that combines GLP-1 agonism with GIPR antagonism (blocking the GIP receptor, as opposed to the GIP agonism in tirzepatide). Berobenatide is a smaller lipidated peptide, a pure GLP-1 agonist relying entirely on biased agonism and albumin binding for its differentiation.<\/p>\n<p>Which approach proves superior in Phase 3 \u2014 if either does \u2014 will not be known until 2028 at the earliest. But the market implications are substantial. Novo Nordisk and Eli Lilly currently dominate the GLP-1 market with weekly injectables. A validated monthly injectable from either Pfizer or Amgen would represent the first pharmacological disruption of that duopoly&#8217;s most profitable segment.<\/p>\n<p>How Blackstone&#8217;s Deal Works \u2014 and What It Tells Us About the Risk<\/p>\n<p>The financial structure of Wednesday&#8217;s deal is itself a case study in modern pharmaceutical development financing.<\/p>\n<p>Blackstone Life Sciences, led by Nicholas Galakatos, <a rel=\"nofollow noopener\" href=\"https:\/\/pharmaphorum.com\/news\/blackstone-closes-record-63bn-life-sciences-fund\" class=\"external_red\" target=\"_blank\">closed Blackstone Life Sciences VI<\/a> in March 2026 at $6.3 billion, the largest fund of its kind, 40% larger than the prior vintage. The fund&#8217;s model is what the industry calls synthetic royalty or milestone-linked development financing: a specialized investor provides capital to fund late-stage clinical development in exchange for future milestone payments and royalties tied to commercial success, without taking any equity or drug-ownership stake.<\/p>\n<p>Under the Pfizer agreement, Blackstone covers up to $1.5 billion in berobenatide R&amp;D costs through 2028. In return, Blackstone is eligible to receive payments contingent on US approval of monthly berobenatide monotherapy and on hitting commercial sales thresholds. Neither party has disclosed the specific milestone amounts or royalty rates \u2014 BMO analysts noted this means it is difficult to quantify the deal&#8217;s long-term impact on Pfizer&#8217;s cash generation if berobenatide succeeds commercially.<\/p>\n<p>The economic logic is symmetrical: Pfizer advances an expensive 10-trial Phase 3 program with $1.5 billion of outside capital, reducing its own R&amp;D cash exposure without issuing new equity (dilutive) or new debt (adds to an already substantial ~$60 billion long-term debt load). Blackstone receives risk-adjusted exposure to berobenatide&#8217;s commercial upside \u2014 with no return if the drug fails FDA review, but significant returns if it reaches blockbuster sales in the obesity market.<\/p>\n<p>&#8220;We are pleased to further expand our relationship with Pfizer and support the broad and rigorous development of berobenatide as the anchor of Pfizer&#8217;s cardiometabolic pipeline,&#8221; said Galakatos in a prepared statement. The phrase &#8220;expand our relationship&#8221; is notable: Blackstone and Pfizer have a prior collaboration, suggesting this deal was built on established institutional trust rather than a cold introduction.<\/p>\n<p>Pfizer&#8217;s Strategic Position: Why This Deal Had to Happen Now<\/p>\n<p>For Pfizer, the Blackstone deal is inseparable from a broader strategic crisis. The company currently faces approximately $21 billion in annual revenues from <a rel=\"nofollow noopener\" href=\"https:\/\/www.biospace.com\/business\/jpm26-pfizer-fast-tracks-obesity-programs-in-race-against-patent-cliff\" class=\"external_red\" target=\"_blank\">products approaching patent expiration<\/a> \u2014 a loss-of-exclusivity headwind estimated at $1.5 billion in 2026, rising to $4.5 billion in 2027 and steeper thereafter. After its COVID-era revenues began falling sharply, Pfizer has been in systematic search of the next franchise-scale product.<\/p>\n<p>The failed oral GLP-1 program \u2014 danuglipron, abandoned in April 2025 after liver enzyme elevations in clinical trials \u2014 made the obesity imperative more urgent. The Metsera acquisition in November 2025, for up to approximately $10 billion, was widely characterized as Pfizer&#8217;s last credible path to obesity market leadership before the competitive window narrowed further. Berobenatide had to work. And the Phase 3 program had to launch fast.<\/p>\n<p>Pfizer has committed to advancing more than 20 clinical trials focused on obesity and related comorbidities in 2026 alone, including the 10 berobenatide Phase 3 studies. At the <a rel=\"nofollow noopener\" href=\"https:\/\/www.pfizer.com\/news\/articles\/pfizer_s_third_quarter_results_reflect_confidence_and_momentum\" class=\"external_red\" target=\"_blank\">Q3 2026 earnings call<\/a> on November 3, the company raised its full-year revenue guidance to $62\u2013$64 billion and noted that 2026 R&amp;D investment is projected at $10.8\u2013$11.8 billion, partly reflecting the Phase 3 ramp. Net interest expense in Q3 was $554 million \u2014 reflecting the ongoing cost of the acquisition-driven balance sheet built up since 2022.<\/p>\n<p>Against that backdrop, transferring up to $1.5 billion in berobenatide development costs to an external partner \u2014 without surrendering any equity or asset ownership \u2014 is a materially different capital allocation choice than what Pfizer has historically made. It signals confidence in berobenatide&#8217;s commercial potential (Blackstone would not write this check without deep diligence supporting a credible regulatory and commercial path) while managing the balance sheet risk of a Phase 3 failure.<\/p>\n<p>Regulatory Backdrop<\/p>\n<p>Berobenatide will need FDA approval as a new molecular entity before it can reach patients. The Phase 3 VESPER program includes studies beyond weight management: knee osteoarthritis and obstructive sleep apnea are explicitly named, suggesting Pfizer is building a broad label strategy similar to what Novo Nordisk and Lilly have pursued for their GLP-1 franchises.<\/p>\n<p>Separately, Pfizer is one of five pharmaceutical companies that received <a rel=\"nofollow noopener\" href=\"https:\/\/www.pharmexec.com\/view\/us-house-committee-investigating-drugmakers-china-drug-trials-report\" class=\"external_red\" target=\"_blank\">House Select Committee on China<\/a> letters in June 2026 regarding clinical trials conducted at Chinese military-affiliated hospitals. That investigation covers historical trial conduct unrelated to berobenatide, whose Phase 3 program is US-based and was initiated after the Metsera acquisition. It represents a reputational and regulatory overhang for Pfizer broadly, but analysts have not tied it directly to the obesity program&#8217;s development timeline.<\/p>\n<p>What Phase 3 Still Has to Prove<\/p>\n<p>Berobenatide enters Phase 3 with promising but incomplete evidence. The key questions the VESPER Phase 3 program must answer:<\/p>\n<p>Efficacy at monthly dosing: The up to 12.3% placebo-adjusted monthly weight loss from Phase 2b must be reproduced \u2014 and ideally improved \u2014 at the Phase 3 scale. Payers and physicians will compare this to tirzepatide&#8217;s ~20\u201322% at 72 weeks (approved) and MariTide&#8217;s up to ~20% at 52 weeks (Phase 2). A definitive monthly label requires Phase 3 data showing durable, clinically meaningful weight loss.<\/p>\n<p>GI tolerability advantage: The biased agonism hypothesis needs clinical confirmation. If Phase 3 shows that berobenatide-treated patients have materially lower GI discontinuation rates than weekly GLP-1 RA historical benchmarks, the adherence argument becomes a commercial reality. If the GI advantage is modest or absent in humans, the drug&#8217;s differentiation story weakens significantly.<\/p>\n<p>Comorbidity outcomes: The osteoarthritis and sleep apnea extensions will determine whether berobenatide can compete for the multi-indication prescribing profile that has driven Wegovy&#8217;s cardiovascular outcomes premium (SELECT trial) and Zepbound&#8217;s commercial expansion.<\/p>\n<p>Safety at scale: No new safety signals in Phase 2, but Phase 3&#8217;s tens of thousands of participants will generate the first large-scale characterization of berobenatide&#8217;s risk profile.<\/p>\n<p>The timeline to any of these answers runs through 2028, at minimum.<\/p>\n<p>What This Means for Readers<\/p>\n<p>For the approximately one in eight American adults who currently use or are considering a GLP-1 drug, the Pfizer-Blackstone deal signals that the competitive landscape is about to become significantly more complex \u2014 and potentially more patient-friendly. If berobenatide clears Phase 3, once-monthly obesity pharmacotherapy could reach pharmacies as early as 2029 or 2030, providing a credible competitor to the weekly-injection duopoly. The monthly interval, if it delivers the adherence improvement the mechanistic case predicts, would represent a meaningful practical upgrade for the millions of patients who struggle with weekly injection schedules.<\/p>\n<p>The molecular engineering that makes monthly dosing possible \u2014 biased agonism preventing receptor desensitization, terminal lipidation enabling active receptor binding while albumin-bound \u2014 reflects genuine scientific progress beyond incremental dosing-schedule optimization. Blackstone&#8217;s up-to-$1.5 billion commitment is, in effect, a structured assessment that this scientific progress is commercially viable and that the FDA pathway is credible. Phase 3 will determine whether that assessment was correct.<\/p>\n","protected":false},"excerpt":{"rendered":"Employees work on the production line at the Novo Nordisk factory in Hilleroed on September 26, 2023. Novo&hellip;\n","protected":false},"author":2,"featured_media":204438,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[54289,90563,3335,52950,272,357,90564,4131,3388],"class_list":["post-204437","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-berobenatide","tag-blackstone-life-sciences","tag-glp-1","tag-glp-1-receptor-agonist","tag-novo-nordisk","tag-obesity","tag-once-monthly-injection","tag-pfizer","tag-weight-loss-drug"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117606580699540290","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/204437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=204437"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/204437\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/204438"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=204437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=204437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=204437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}